Below are the most recent publications written about "Ventricular Dysfunction" by people in Profiles.
-
Schroeder LW, Chowdhury SM, Burnette AL, Kavarana MN, Hamilton Baker G, Savage AJ, Atz AM, Butts RJ. Longer Ischemic Time is Associated with Increased Ventricular Stiffness as Measured by Pressure-Volume Loop Analysis in Pediatric Heart Transplant Recipients. Pediatr Cardiol. 2018 Feb; 39(2):324-328.
-
Iyer RP, de Castro Brás LE, Patterson NL, Bhowmick M, Flynn ER, Asher M, Cannon PL, Deleon-Pennell KY, Fields GB, Lindsey ML. Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution. J Mol Cell Cardiol. 2016 Nov; 100:109-117.
-
Miller PE, Scholten EL, Desai CS, Tedford RJ. A patient with systolic dysfunction and an alternating axis. JAMA Intern Med. 2014 Dec; 174(12):2027-8.
-
Kelly KM, Tocchetti CG, Lyashkov A, Tarwater PM, Bedja D, Graham DR, Beck SE, Metcalf Pate KA, Queen SE, Adams RJ, Paolocci N, Mankowski JL. CCR5 inhibition prevents cardiac dysfunction in the SIV/macaque model of HIV. J Am Heart Assoc. 2014 Apr 02; 3(2):e000874.
-
Parks JL, Taylor MH, Parks LP, Silver RM. Systemic sclerosis and the heart. Rheum Dis Clin North Am. 2014 Feb; 40(1):87-102.
-
McCrindle BW, Zak V, Sleeper LA, Paridon SM, Colan SD, Geva T, Mahony L, Li JS, Breitbart RE, Margossian R, Williams RV, Gersony WM, Atz AM. Laboratory measures of exercise capacity and ventricular characteristics and function are weakly associated with functional health status after Fontan procedure. Circulation. 2010 Jan 05; 121(1):34-42.
-
Simon RD, Sturdivant JL, Leman RB, Wharton JM, Gold MR. The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009 Jan; 32(1):24-8.
-
Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, Lee KL, Bardy GH. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation. 2008 Nov 11; 118(20):2022-8.
-
Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JM, Artis E, Purkayastha D, Thomas JD, Solomon SD. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006 Aug; 152(2):246-52.